A new study (the ATOMIC2 trial), presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and published simultaneously in The Lancet Respiratory Medicine, shows the antimicrobial drug azithromycin - already approved for use in multiple infections - does not prevent mild COVID-19 cases progressing to hospitalisation or death.
